CPT® Code 86043

Acetylcholine receptor (AChR) antibodies are specific proteins that can be found in the bloodstream of individuals diagnosed with myasthenia gravis (MG), a rare neuromuscular disorder characterized by muscle weakness and fatigue. Myasthenia gravis can manifest in two primary forms: ocular myasthenia gravis, which primarily affects the eye muscles, and generalized myasthenia gravis, which impacts a broader range of voluntary muscles throughout the body. Symptoms associated with ocular myasthenia gravis may include drooping eyelids, double vision, and weakness in the eye muscles. In contrast, generalized myasthenia gravis can lead to more severe symptoms, such as weakness in neck muscles, difficulties with chewing, swallowing, or speaking, slurred speech, and challenges with walking or breathing. It is noteworthy that approximately 15% of individuals with myasthenia gravis experience only ocular symptoms. The presence of AChR antibodies disrupts the normal communication between nerves and muscles by interfering with the action of acetylcholine, which is the neurotransmitter responsible for transmitting signals from nerves to muscles. Specifically, modulating antibodies can cause the receptors to be internalized within the cell membrane and subsequently degraded, resulting in reduced expression of these receptors and potentially correlating with increased severity of the disease. To diagnose the presence of AChR antibodies, a sample of venous blood is collected, and semi-quantitative flow cytometry is employed for testing. A positive result can confirm the diagnosis in symptomatic individuals; however, it is important to note that elevated AChR antibody levels may also be observed in patients with thymoma, a type of tumor associated with the thymus gland. It is estimated that only 10% to 15% of individuals with myasthenia gravis will test negative for AChR antibodies, necessitating further testing for other antibodies, such as muscle-specific kinase (MuSK) antibodies. The modulating antibody test is typically conducted when AChR binding antibody levels fall within an indeterminate range of 25% to 41%, with levels of 46% or higher being classified as positive. However, the likelihood of detecting modulating antibodies in patients who are negative for binding and blocking antibodies is less than 0.4%.